CD19 and leukemia: Remarkably, 25% of mice treated with ponatinib plus CD19@NP/17-DMAG mounted a protective memory response, preventing leukemia re-establishment over 100 days, however all mice treated with ponatinib plus 17-DMAG eventually succumbed to leukemia (Figure 7F).